Active clinical trials for "HTLV-II Infections"

This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50).

The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening assay (Avioq ELISA).

The purpose of this study is: To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4. To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive population.